Cencora, Inc. Revenue & Financials

Cencora, Inc. reported $278.0 billion in global revenue for the fiscal year ended September 30, 2024, representing a 9% increase compared to FY2023, driven by the continued robust commercial scaling of the specialty pharmacy portfolio and the expansion of its global commercialization services network. The company's operating income surged to $3.5 billion, reflecting a highly efficient cost structure that delivered a 3.0% gross margin and a 1.3% operating margin, figures that are characteristic of the high-volume, low-margin pharmaceutical wholesale distribution industry. Net income reached $2.0 billion, while free cash flow generation remained exceptionally strong at $4.5 billion, providing the financial flexibility to fund strategic acquisitions, service the $6.4 billion opioid litigation settlement, and execute share repurchases. The FY2024 financial results highlight a company in the midst of a successful portfolio transition. While the growth rate of the core US Healthcare Solutions segment has begun to normalize as it reaches saturation in the traditional wholesale market, the combined sales of the specialty pharmacy portfolio and the global commercialization services segment demonstrated that the company's next generation of assets is beginning to achieve commercial scale and offset the margin compression in the legacy business. The company's gross margin remained stable at approximately 3.0%, reflecting the intense competitive pressure from retail pharmacy consolidation and the impact of 340B program chargebacks, despite the higher margins contributed by the specialty and logistics segments. Selling, general, and administrative expenses were tightly controlled, growing at a slower rate than revenue, which contributed to the margin expansion. The balance sheet remains heavily leveraged but structurally improving, with $12.5 billion in total long-term debt, allowing Cencora to maintain a systematic debt reduction program while executing strategic acquisitions in the specialty pharmacy space. This capital allocation strategy is designed to support the credit rating during the transition period from the AmerisourceBergen era to the Cencora era, signaling management's confidence in the long-term cash generation capabilities of the diversified healthcare services model. The FY2024 financial performance validates the strategic decision to pivot aggressively toward specialty and logistics assets, as the addition of Alto Pharmacy and the expansion of World Courier have significantly improved the company's overall revenue diversification and reduced its exposure to the highly competitive wholesale distribution market. The detailed breakdown of the FY2024 income statement reveals the underlying drivers of this financial success. Net sales of $278.0 billion were composed of $245.0 billion from the US Healthcare Solutions segment, $18.0 billion from the Global Commercialization and Services segment, and $15.0 billion from the specialty pharmacy and other segments. The US market remains the most profitable region, contributing approximately 88% of total revenue but an even higher percentage of operating profit due to the significantly higher volumes and operational scale in the United States compared to international markets. The cost of goods sold (COGS) was $269.6 billion, resulting in a gross profit of $8.4 billion and a gross margin of 3.0%. This low gross margin is characteristic of the pharmaceutical wholesale distribution industry and reflects the intense competitive pressure from McKesson and Cardinal Health, and the consolidated buying power of retail giants like CVS Health and Walgreens Boots Alliance. Research and development expenses were minimal, as the company's business model relies on operational innovation and supply chain optimization rather than traditional drug discovery. Selling, general, and administrative (SG&A) expenses were $4.9 billion, or 1.8% of net sales, reflecting the significant operational investment required to maintain the national distribution network and navigate the complex regulatory landscape. The operating income of $3.5 billion was achieved after deducting amortization of intangible assets and other operating expenses, resulting in an operating margin of 1.3%. This margin performance is a testament to the company's rigorous cost management practices and the high operating leverage inherent in the pharmaceutical distribution business model. The net income of $2.0 billion was achieved after deducting income taxes and interest expense, resulting in an effective tax rate of 22.5%, which is slightly below the statutory US rate due to the favorable geographic mix of the company's profits and the utilization of various tax credits and incentives. The strong cash flow generation of $4.5 billion provided the company with the financial flexibility to return $2.5 billion to shareholders through dividends and share buybacks, while also funding $1.0 billion in strategic acquisitions and capital expenditures, and making the first annual payment of $400 million toward the opioid litigation settlement. The balance sheet at the end of FY2024 showed total assets of $75.0 billion, total liabilities of $62.5 billion, and total equity of $12.5 billion, resulting in a debt-to-equity ratio of 1.0, which is significantly improved from the 2000s peak but still reflects the highly leveraged nature of the corporate structure.